NF-κB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor
2007

DHMEQ suppresses osteoclast formation in mouse arthritis

Sample size: 31 publication 10 minutes Evidence: moderate

Author Information

Author(s): Kubota Tetsuo, Hoshino Machiko, Aoki Kazuhiro, Ohya Keiichi, Komano Yukiko, Nanki Toshihiro, Miyasaka Nobuyuki, Umezawa Kazuo

Primary Institution: Tokyo Medical and Dental University

Hypothesis

Does the NF-κB inhibitor DHMEQ affect osteoclastogenesis in mouse arthritis models?

Conclusion

DHMEQ significantly suppresses osteoclast differentiation in collagen-induced mouse arthritis.

Supporting Evidence

  • DHMEQ reduced the number of osteoclasts in arthritic joints.
  • Serum levels of RANKL, osteoprotegerin, and M-CSF were not significantly affected by DHMEQ treatment.
  • DHMEQ suppressed NFATc1 expression in the joints of treated mice.
  • Human osteoclast differentiation was also inhibited by DHMEQ in vitro.

Takeaway

A medicine called DHMEQ helps stop certain cells that break down bones from working too much in mice with arthritis.

Methodology

The study used a mouse model of collagen-induced arthritis and in vitro cultures of human cells to assess the effects of DHMEQ on osteoclastogenesis.

Limitations

The study primarily focused on mouse models and may not fully translate to human conditions.

Participant Demographics

The study included male DBA/1J mice and fibroblast-like synovial cells from six female RA patients aged 67.3 ± 9.1 years.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/ar2298

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication